Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 238

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 238
---
 Stock. There is no
assurance that the holders of the Warrants will elect to exercise any or all of such Warrants. As of the date of this Annual Report,
(i) all of the Private Placement Warrants and Public Warrants, which have an exercise price of $1,150.00 per share, (ii) December 2024 Common Warrants, which have an exercise price of $5.61 per share, (iii) January 2025 Common Warrants, which have an exercise price of $5.82
per share, (iv) February 2025 Common Warrants to purchase shares of Common Stock, at a current exercise price of $1.96 per share issued
by the Company in a public offering on February 7, 2025. and (v) all of the Series A Warrants,
which have a current exercise price of $139.00 per share, are “out of the money,” meaning the exercise price is higher
than the market price of our Common Stock. Holders of such “out of the money” Warrants are not likely to exercise such
Warrants. There can be no assurance that such Warrants will be in the money prior to their respective expiration dates, and
therefore, we may not receive any cash proceeds from the exercise of such Warrants.

An active trading market for our Common
Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. The price of our Common Stock may be
extremely volatile, and stockholders could lose all or part of their investment.

The trading price of our
Common Stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are
beyond our control, including limited trading volume. In addition to the factors discussed in this “Risk Factors” section
and elsewhere in this Annual Report, these factors include:

●the
                                            commencement, enrollment or results of any planned and future preclinical studies and clinical
                                            trials of our product candidates or changes in the development status of our product candidates;

●any
                                            delay in our regulatory filings for our product candidates and any adverse development or
                                            perceived adverse development with respect to the applicable regulatory authority’s
                                            review of such filings;

●adverse
                                            results from or delays in preclinical studies and clinical trials of our product candidates,
                                            including as a result of clinical holds, safety events, enrollment difficulties, or study
                                            protocol amendments;

●our